The Quantellect read.As of Nov 19, 2026, 23 active firms cover Revolution Medicines Inc: 22 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $122.00 to $320.00 (about 2.6x), a sign of real disagreement on valuation. The average target of $234.18 sits 47% above the current $159.73. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 19 to 22 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.81 next quarter toward $-3.10 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS23 active firms
Buy
Strong Buy00%
Buy2296%
Neutral14%
Sell00%
Strong Sell00%
Based on 23 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$234.18
+46.6% upside
Average target across 22 active firms as of Nov 19, 2026 vs $159.73 current
Highest Target$320.00
Average Target$234.18
Lowest Target$122.00
Detailed analyst forecasts for RVMD
Showing 1–24 of 24 named analysts shown · 23 active firms in the rating projection
As of Nov 19, 2026, 22 of 23 active firms rate RVMD a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
RVMD EPS & revenue forecast
EPS · NEXT QUARTER
$-0.81
Range $-2.35 – $0.38 · 11 analysts · -65% YoY
Next period, 11 analysts expect Revolution Medicines Inc to earn $-0.81 a share (range $-2.35 – $0.38), versus $-2.29 a year earlier. Full-year consensus is $-8.30, growing to $-3.10 the year after.
REVENUE · NEXT QUARTER
$462.0M
Range $137.0M – $685.0M · 11 analysts
Revenue is expected to reach $462.0M (range $137.0M – $685.0M). Full-year consensus is $625.4M, rising to $2.0B next year.
Top analysts covering Revolution Medicines Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RVMD.
#1
Michael Schmidt
Guggenheim · Rank #4
Buy
$298.00+86.6% to target
Overall win rate
53%
+ Follow
#2
Leonid Timashev
RBC Capital · Rank #27
Buy
$321.00+101.0% to target
Overall win rate
52%
+ Follow
#3
Brian Cheng
JP Morgan · Rank #87
Buy
No targeton RVMD
Overall win rate
51%
+ Follow
#4
Peter Lawson
Barclays · Rank #89
Buy
$72.00-54.9% to target
Overall win rate
45%
+ Follow
#5
Ami Fadia
Needham · Rank #92
Buy
$275.00+72.2% to target
Overall win rate
46%
+ Follow
RVMD stock forecast FAQ
What is RVMD's average 12-month price target?+
The 22 active firms with a live target average $234.18 for Revolution Medicines Inc over the next 12 months, ranging from a $320.00 high to a $122.00 low, as of Nov 19, 2026.
Is RVMD stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 23 active firms as of Nov 19, 2026, 22 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for RVMD?+
The Street-high target is $320.00 (Evercore ISI Group), and the Street-low is $122.00 (JP Morgan). The average of all 22 active-firm targets is $234.18.
How many active Wall Street firms cover RVMD?+
23 active firms have a recognized rating on Revolution Medicines Inc as of Nov 19, 2026, and 22 active firms carry a live 12-month price target.
Who is the most accurate analyst covering RVMD?+
Among analysts who currently cover RVMD, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #4). Their current call is Buy with a $298.00 target.
What is Revolution Medicines Inc's projected EPS for next quarter?+
The consensus estimate is $-0.81 per share (range $-2.35 – $0.38) across 11 analysts. Full-year EPS is projected at $-8.30, rising to $-3.10 the following year.
How much revenue is Revolution Medicines Inc expected to report next quarter?+
Consensus revenue is $462.0M (range $137.0M – $685.0M). Full-year revenue is projected at $625.4M, growing to $2.0B next year.
Have analysts been upgrading or downgrading RVMD lately?+
As of Nov 19, 2026, 22 of 23 active firms rate RVMD a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RVMD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.